Time-Cap Labs, Inc. has been acquired by Marksans Pharma Ltd.
The founder and owner of Time-Cap Labs, Inc. has sold the company to Marksans Pharma Limited for an undisclosed consideration.
Founded in 1978 and based in Farmingdale, New York, Time-Cap Labs, Inc. manufactures and supplies generic pharmaceuticals and over-the-counter drugs. The company specializes in delayed and sustained release dosages. It offers various formulations, including analgesics, laxatives, dietary supplements, cough and cold medications, prescription drugs, antacids, and other products. The company offers its products to large and small wholesalers and distributors.
Marksans Pharma Limited, together with its subsidiaries, is engaged in the research, manufacture, and marketing of generic pharmaceutical formulations worldwide. Its product portfolio covers primary therapeutic segments of CVS, analgesics, decongestants, gastrointestinal, cardiovascular, anti-diabetics, central nervous system, oncology, anti-allergic drugs, and others. It also manufactures and distributes over-the-counter pharmaceutical products in the areas of cough and cold remedies, galenicals, vitamins, palliative and healthcare items, oils, antiseptics, and disinfectants; and offers contract research and manufacturing services to global pharmaceutical companies. Marksans Pharma Limited is headquartered in Mumbai, India.
One of Oaklins' teams in the USA served as the exclusive financial advisor to the seller in this transaction.
Talk to the deal team
Paul R. Smolevitz
Oaklins TM Capital
James McLaren
Oaklins TM Capital
Related deals
The Providence Projects has been acquired by UKAT Group
Celebrity-success rehabilitation center, The Providence Projects, has joined The UK Addiction Treatment (UKAT) Group, backed by Sullivan Street Equity Partners.
Learn moreSt. Claraspital AG has been acquired by University Hospital Basel
University Hospital Basel (USB) has acquired St. Claraspital AG, expanding its network of specialized care and integrated services. With St. Claraspital’s strong community presence, expertise in acute and rehabilitation medicine and established outpatient clinics, this merger enhances USB’s ability to provide seamless, patient-centered treatment across the continuum of care. The completion of the transaction is subject to clearance by the Swiss Competition Commission (COMCO).
Learn moreRAM Infotechnology has acquired Interoperability Group with support from Keensight Capital
RAM Infotechnology (RAM-IT) has acquired Interoperability Group, a leading Dutch provider of healthcare IT solutions, with the support of Keensight Capital, a leading European growth buy-out investor specializing in technology and healthcare.
Learn more